Médecins Sans Frontières

Médecins Sans Frontières TB field research in Tajikistan, Uzbekistan and Kyrgyzstan

 

Read More →

MSF open letter to G20 Health Ministers highlights 3 global health priority areas

Médecins Sans Frontières: Open letter from MSF to the Meeting of the G20 Health Ministers

Read More →

MSF urges pharmaceutical corporations to release clinical data to help develop urgently needed new TB regimens

Médecins Sans Frontières (MSF) urges Sequella and Pfizer to provide open access to all existing clinical data for sutezolid to help accelerate the research and development of urgently needed new, lifesaving TB treatment regimes.

Read More →

Fewer than 5% of people in need are treated with new TB drugs, nearly four years after their approval

Companies and countries must take urgent action to increase access to these life-saving treatments.

Read More →

Georgia: endTB partnership launches clinical trial to target toughest strains of TB

TBILISI (Georgia), 6 March 2017 – Médecins Sans Frontières (MSF), Partners In Health (PIH) and other leading medical organizations have launched a major clinical trial which seeks to revolutionize treatment for the toughest strains of tuberculosis (TB), the world’s leading infectious disease killer. The first patient started treatment in Georgia last week.

Read More →

Pioneering new MSF-run clinical trial for drug-resistant TB treatment starts

A pioneering new clinical trial aiming to find a radically improved course of treatment for drug-resistant tuberculosis (TB) began on 17th January 2017, when the first patient took the first pill in Uzbekistan.

Read More →

MSF calls on Johnson & Johnson to improve access to bedaquiline

Médecins Sans Frontières (MSF) urges Johnson & Johnson to ensure widespread access to bedaquiline for the treatment of multidrug-resistant TB.

Read More →

MSF and Stop TB Partnership urge further action to address TB crisis at BRICS health meeting

Geneva, 16 December 2016

Read More →

MSF urges the Global Fund to freeze implementation of transition plans

Médecins Sans Frontières (MSF) expressed concerns about the Global Fund’s policies on allocation, co-financing, and transition.

Read More →

Tajikistan: Stories from MSF's paediatric TB projects

Delamanid is one of the first new TB medicines in over 50 years, and recently the project team in Dushanbe, Tajikistan's capital, started treating a young TB patient with it. It follows several months of preparations and negotiations with the Ministry of Health and its counterparts.

Read More →

Page 1 of 4 · Total posts: 10

1 2 Last→